Literature DB >> 20043025

Respiratory syncytial virus market.

Shane Storey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20043025     DOI： 10.1038/nrd3075

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  12 in total

1.  Inhibition of respiratory viruses by nasally administered siRNA.

Authors:  Vira Bitko; Alla Musiyenko; Olena Shulyayeva; Sailen Barik
Journal:  Nat Med       Date:  2004-12-26       Impact factor: 53.440

2.  Impact of RSV: implications for managed care.

Authors:  Doris Makari; J Michael Hoopes; Norman White
Journal:  Manag Care       Date:  2009-01

Review 3.  Motavizumab for the prevention of respiratory syncytial virus infection in infants.

Authors:  Michelle A Gill; Robert C Welliver
Journal:  Expert Opin Biol Ther       Date:  2009-10       Impact factor: 4.388

Review 4.  RSV infection in the adult population.

Authors:  Julio A Ramirez
Journal:  Manag Care       Date:  2008-11

Review 5.  Respiratory syncytial virus infection in adults.

Authors:  Yoshihiko Murata
Journal:  Curr Opin Pulm Med       Date:  2008-05       Impact factor: 3.155

6.  Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.

Authors:  V A Fulginiti; J J Eller; O F Sieber; J W Joyner; M Minamitani; G Meiklejohn
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

7.  Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria.

Authors:  Bernhard Resch; Walter Gusenleitner; Mark J C Nuijten; Maximilian Lebmeier; Wolfgang Wittenberg
Journal:  Clin Ther       Date:  2008-04       Impact factor: 3.393

Review 8.  Challenges in developing a pediatric RSV vaccine.

Authors:  Jeanne H Schickli; Filip Dubovsky; Roderick S Tang
Journal:  Hum Vaccin       Date:  2009-09-28

9.  1,4-benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate.

Authors:  Elisa A Henderson; Dagmar G Alber; Robert C Baxter; Sian K Bithell; Joanna Budworth; Malcolm C Carter; Ann Chubb; G Stuart Cockerill; Verity C L Dowdell; Ian J Fraser; Robert A Harris; Sally J Keegan; Richard D Kelsey; James A Lumley; Jeremy N Stables; Natasha Weerasekera; Lara J Wilson; Kenneth L Powell
Journal:  J Med Chem       Date:  2007-03-07       Impact factor: 7.446

Review 10.  Emerging drugs for respiratory syncytial virus infection.

Authors:  Wieslawa Olszewska; Peter Openshaw
Journal:  Expert Opin Emerg Drugs       Date:  2009-06       Impact factor: 4.191
View more
  14 in total

Review 1.  Strategies and challenges for the next generation of therapeutic antibodies.

Authors:  Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

Review 2.  The present state of the art in expression, production and characterization of monoclonal antibodies.

Authors:  Christopher L Gaughan
Journal:  Mol Divers       Date:  2015-08-25       Impact factor: 2.943

3.  Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.

Authors:  Alexander Gutfraind; Alison P Galvani; Lauren Ancel Meyers
Journal:  JAMA Pediatr       Date:  2015-04       Impact factor: 16.193

4.  Evolutionary dynamics of group A and B respiratory syncytial virus in China, 2009-2018.

Authors:  Yingying Ma; Haixia Jiang; Zhenzhou Wan; Shenwei Li; Yingxue Li; Wei Wang; Xia Jin; Yanpeng Li; Chiyu Zhang
Journal:  Arch Virol       Date:  2021-06-15       Impact factor: 2.574

5.  p38 and OGT sequestration into viral inclusion bodies in cells infected with human respiratory syncytial virus suppresses MK2 activities and stress granule assembly.

Authors:  Jens Fricke; Lily Y Koo; Charles R Brown; Peter L Collins
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

6.  Discovery of 3,3'-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection.

Authors:  Weihua Shi; Zhigan Jiang; Haiying He; Fubiao Xiao; Fusen Lin; Ya Sun; Lijuan Hou; Liang Shen; Lixia Han; Minggao Zeng; Kunmin Lai; Zhengxian Gu; Xinsheng Chen; Tao Zhao; Li Guo; Chun Yang; Jian Li; Shuhui Chen
Journal:  ACS Med Chem Lett       Date:  2018-01-10       Impact factor: 4.345

7.  Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide.

Authors:  Manuela Donalisio; Marco Rusnati; Valeria Cagno; Andrea Civra; Antonella Bugatti; Andrea Giuliani; Giovanna Pirri; Marco Volante; Mauro Papotti; Santo Landolfo; David Lembo
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

Review 8.  An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children.

Authors:  Harish Nair; Vasundhara R Verma; Evropi Theodoratou; Lina Zgaga; Tanvir Huda; Eric A F Simões; Peter F Wright; Igor Rudan; Harry Campbell
Journal:  BMC Public Health       Date:  2011-04-13       Impact factor: 3.295

Review 9.  Monoclonal antibodies and toxins--a perspective on function and isotype.

Authors:  Siu-Kei Chow; Arturo Casadevall
Journal:  Toxins (Basel)       Date:  2012-06-11       Impact factor: 4.546

10.  Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model.

Authors:  Larry Zeitlin; Ognian Bohorov; Natasha Bohorova; Andrew Hiatt; Do H Kim; Michael H Pauly; Jesus Velasco; Kevin J Whaley; Dale L Barnard; John T Bates; James E Crowe; Pedro A Piedra; Brian E Gilbert
Journal:  MAbs       Date:  2013-02-08       Impact factor: 5.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.